Literature DB >> 9594673

Effectiveness of excision of pre-ulcerative Buruli lesions in field situations in a rural district in Ghana.

G Amofah1, S Asamoah, C Afram-Gyening.   

Abstract

The effectiveness of excision of pre-ulcerative Buruli lesions in field situations was assessed in a prospective study in an endemic focus in rural Ghana. All 50 patients, clinically diagnosed as having pre-ulcerative Buruli lesions, had their lesions excised followed by primary suturing. The patients were then followed up until the wound healed and thereafter for a year or until recurrence. The median duration for complete healing after excision was 31.5 days while the 1-year recurrence rate was 16%. None of the patients had any form of deformity after healing in contrast with the usual consequences of other forms of treatment. Our findings suggest that excision of pre-ulcerative Buruli lesions is effective in preventing deformities but less so for preventing recurrence of lesion.

Entities:  

Mesh:

Year:  1998        PMID: 9594673     DOI: 10.1177/004947559802800208

Source DB:  PubMed          Journal:  Trop Doct        ISSN: 0049-4755            Impact factor:   0.731


  20 in total

1.  Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans.

Authors:  S Etuaful; B Carbonnelle; J Grosset; S Lucas; C Horsfield; R Phillips; M Evans; D Ofori-Adjei; E Klustse; J Owusu-Boateng; G K Amedofu; P Awuah; E Ampadu; G Amofah; K Asiedu; M Wansbrough-Jones
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

2.  Clinical efficacy of combination of rifampin and streptomycin for treatment of Mycobacterium ulcerans disease.

Authors:  Fred Stephen Sarfo; Richard Phillips; Kingsley Asiedu; Edwin Ampadu; Nana Bobi; E Adentwe; Awuli Lartey; Ishmael Tetteh; M Wansbrough-Jones
Journal:  Antimicrob Agents Chemother       Date:  2010-06-21       Impact factor: 5.191

3.  What does detection of Mycobacterium ulcerans DNA in the margin of an excised Buruli ulcer lesion tell us?

Authors:  Simona Rondini; Ernestina Mensah-Quainoo; Thomas Junghanss; Gerd Pluschke
Journal:  J Clin Microbiol       Date:  2006-08-23       Impact factor: 5.948

4.  Serologic response to culture filtrate antigens of Mycobacterium ulcerans during Buruli ulcer disease.

Authors:  K M Dobos; E A Spotts; B J Marston; C R Horsburgh; C H King
Journal:  Emerg Infect Dis       Date:  2000 Mar-Apr       Impact factor: 6.883

5.  Excision of pre-ulcerative forms of Buruli ulcer disease: a curative treatment?

Authors:  K-H Herbinger; D Brieske; J Nitschke; V Siegmund; W Thompson; E Klutse; N Y Awua-Boateng; E Bruhl; L Kunaa; M Schunk; O Adjei; T Löscher; G Bretzel
Journal:  Infection       Date:  2008-12-03       Impact factor: 3.553

6.  Sensitivity of PCR targeting Mycobacterium ulcerans by use of fine-needle aspirates for diagnosis of Buruli ulcer.

Authors:  R O Phillips; F S Sarfo; F Osei-Sarpong; A Boateng; I Tetteh; A Lartey; E Adentwe; W Opare; K B Asiedu; M Wansbrough-Jones
Journal:  J Clin Microbiol       Date:  2009-02-09       Impact factor: 5.948

7.  Immunoglobulin M antibody responses to Mycobacterium ulcerans allow discrimination between cases of active Buruli ulcer disease and matched family controls in areas where the disease is endemic.

Authors:  Daniel M N Okenu; Lazarus O Ofielu; Kirk A Easley; Jeannette Guarner; Ellen A Spotts Whitney; Pratima L Raghunathan; Ymkje Stienstra; Kwame Asamoa; Tjip S van der Werf; Winette T A van der Graaf; Jordan W Tappero; David A Ashford; C Harold King
Journal:  Clin Diagn Lab Immunol       Date:  2004-03

8.  Systemic and local interferon-gamma production following Mycobacterium ulcerans infection.

Authors:  H S Schipper; B Rutgers; M G Huitema; S N Etuaful; B D Westenbrink; P C Limburg; W Timens; T S van der Werf
Journal:  Clin Exp Immunol       Date:  2007-09-27       Impact factor: 4.330

9.  Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (Mycobacterium ulcerans disease).

Authors:  Annick Chauty; Marie-Françoise Ardant; Ambroise Adeye; Hélène Euverte; Augustin Guédénon; Christian Johnson; Jacques Aubry; Eric Nuermberger; Jacques Grosset
Journal:  Antimicrob Agents Chemother       Date:  2007-05-25       Impact factor: 5.191

10.  Buruli ulcer surveillance, Benin, 2003-2005.

Authors:  Ghislain Emmanuel Sopoh; Roch Christian Johnson; Annick Chauty; Ange Dodji Dossou; Julia Aguiar; Olivier Salmon; Françoise Portaels; Kingsley Asiedu
Journal:  Emerg Infect Dis       Date:  2007-09       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.